SUNRISE Trial for Oral Steroid Dependent Asthma Request More Information Trial Objective People with severe asthma are often dependent on oral corticosteroids, such as prednisone, to treat their condition. Researchers are currently investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for these steroid medications. In this study, tezepelumab will be compared against a treatment that does not contain any active medication, called a placebo. Either tezepelumab or the placebo will be given as an injection to study participants. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults ages 18-80 with a documented asthma diagnosis for at least 1 year requiring daily oral steroids for at least 6 months in addition to inhaled steroid treatments. Other criteria will be evaluated to see if you may participate in this study. Age: 18-80 Gender: Any Gender Estimated Time Commitment 14 visits over approximately 12 months. Most visits will last about 2 hours, but a few could take up to 4 hours. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Allen Stevens 720-862-6613 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors AstraZeneca Principal Investigators Michael Wechsler, MD, MMSc + × Michael Wechsler, MD, MMSc Director, The Cohen Family Asthma Institute Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective People with severe asthma are often dependent on oral corticosteroids, such as prednisone, to treat their condition. Researchers are currently investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for these steroid medications. In this study, tezepelumab will be compared against a treatment that does not contain any active medication, called a placebo. Either tezepelumab or the placebo will be given as an injection to study participants.